Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Otsuka

Status and phase: Withdrawn; Phase 4

Conditions: Major Depressive Disorder (MDD)

Treatments: Drug: Brexpiprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT05504486

331-201-00376

Details and patient eligibility

About

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 65 year of age
• Major Depressive Disorder (MDD) with symptoms of anxiety
• Stable treatment with less than 50% improvement

Exclusion criteria

• Contraindicated to perform fMRI scan
• Previous exposure to brexpiprazole

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Arm 1

Experimental group

Description:

Brexpiprazole

Treatment:

Drug: Brexpiprazole